Update of current evidences in breast cancer multidisciplinary management
Breast cancer is acknowledged as an international priority in health care. It is currently the most common neoplasm and leading cause of cancer death in women worldwide, with demographic trends indicating a continuous increase in incidence.
Despite these alarming statistics, evolving evidence-based guidelines in leading disciplines as precision testing, imaging, surgery and radiation-medical oncology resulted in a steady improvement of survival rates.
Today, breast cancer patients are treated according refined diagnostic and treatment algorithms, that require the expertise of a wide range of specialists, in order to formulate case-sensitive and patient-centered treatment strategies. As a result, current evidences confirmed the “Multidisciplinary Breast Unit” model as the only successful environment where dedicated specialists can work in synergy, generating a significant improvement of survival rates and patient’s quality of life.
This focused issue is specifically thought to provide the reader an insight of most recent evidences regarding radiology and molecular imaging, oncoplastic and reconstructive surgery, axillary staging and treatment, BRCA mutation carriers and HER2 positive management, novel integrated therapies results and other topics whose results are constantly debated in literature ant that are key elements in everyday multidisciplinary breast cancer management.
Acknowledgments
Funding: None.
Footnote
Provenance and Peer Review: This article was commissioned by the editorial office, Translational Cancer Research for the series “Update of Current Evidences in Breast Cancer Multidisciplinary Management”. The article did not undergo external peer review.
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.02.11). The series “Update of Current Evidences in Breast Cancer Multidisciplinary Management” was commissioned by the editorial office without any funding or sponsorship. GF served as the unpaid Guest Editor of the series and serves as an unpaid editorial board member of Translational Cancer Research from Nov 2016 to Dec 2018. AMF and RM served as the unpaid Guest Editors of the series. The authors have no other conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
